Catalent (CTLT) is Downgraded by Wells Fargo to Market Perform

Catalent (CTLT) is Downgraded by Wells Fargo to Market Perform , according to the research report released to the investors. Earlier the firm had a rating of Outperform on the company shares. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.

Shares of Catalent, Inc. (NYSE:CTLT) ended Thursday session in red amid volatile trading. The shares closed down 0.18 points or 0.68% at $26.36 with 500,993 shares getting traded. Post opening the session at $26.75, the shares hit an intraday low of $26.34 and an intraday high of $27.05 and the price vacillated in this range throughout the day. The company has a market cap of $3,282 million and the number of outstanding shares has been calculated to be 124,521,872 shares. The 52-week high of Catalent, Inc. (NYSE:CTLT) is $34.415 and the 52-week low is $23.63.

During the last several months other analysts have commented on the company rating. Equity Analysts at the Brokerage Firm, Raymond James, downgrades their rating on the shares of Catalent, Inc. (NYSE:CTLT). Raymond James has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on December 9, 2015.

Analysts at Zacks have given a short term rating of hold on Catalent, Inc. (NYSE:CTLT) with a rank of 3. The shares has received an average rating of 1.72 from 9 brokerage firms. 5 analysts have rated the company as a strong buy. The shares has been rated as hold from 3 Wall Street Analysts. 1 analysts have suggested buying the shares.

Catalent, Inc. (NYSE:CTLT) should head towards $32.07 per share according to 7 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $29 per share. The higher price estimate target is at $36 according to the Analysts.

Shares of Catalent, Inc. appreciated by 0.27% during the last five trading days but lost 2.04% on a 4-week basis. Catalent, Inc. has dropped 6.79% during the last 3-month period . Year-to-Date the stock performance stands at -5.45%.

Catalent, Inc. is a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company operates in three segments: Oral Technologies, Medication Delivery Solutions and Development & Clinical Services. Its oral, injectable, and respiratory delivery technologies address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. It is advanced delivery technology platforms, broad and deep intellectual property, and formulation, manufacturing and regulatory enable its customers to develop more products and better treatments. The Company provides a number of differentiated technologies, products and service offerings to its customers across a delivery technologies and development solutions platforms.